-
A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
This study wants to see if a medicine called disitamab vedotin (designed to go straight to cancer cells and slow down or shrink the cancer ... -
A Phase 2 Multi Cohort Open Label Multi Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48 ADC) Alone and in Combination with Pembrolizumab in Subjects with Locally Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
This research study is testing two treatments for a type of bladder cancer (Urothelial Carcinoma that expresses HER2) that has spread or is hard to ...
-
A Phase 2a Study with Safety Run-in to Evaluate the Safety Tolerability and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
This is a medical study testing a drug called FF-10832 alone and with another medicine called pembrolizumab for patients with advanced solid tumors. First, patients ...
-
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
This study is examining how well a new treatment called N-803, combined with a standard treatment called BCG, works compared to just using BCG alone ...
-
A phase IV study of Apricity C.A.R.E. program for Cancer Adverse events Rapid Evaluation to improve treatment outcomes of ethnic/racial minority non-small cell lung cancer (NSCLC) patients receiving immunotherapy
A phase IV study of Apricity C.A.R.E. program for Cancer Adverse events Rapid Evaluation to improve treatment outcomes of ethnic/racial minority ... -
A multicenter open label Phase 2 study to evaluate the efficacy and saftey of Sutetnib maleate capsule in locally advanced or metastatic NSCLC
This study is for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. The main goal is to see if ...